Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
Search
Boehringer Ingelheim Cares Product Donations Program
Boehringer Ingelheim Cares Product Donations Program
eeo_is_the_law.pdf
An Eye for the Big Picture | PDF
The Globalization of Crime | PDF
For Your SweetHeart Survey
For Your SweetHeart | Campaign Facts
eeo_is_the_law
EEO is the Law Poster
Athens
eeo_is_the_law
The BI Cares Patient Assistance Program - Editable Form
The BI Cares Patient Assistance Program - Gilotrif® - Fillable Form
The BI Cares Patient Assistance Program - Ofev® - Fillable Form
The BI Cares Patient Assistance Program
The BI Cares Patient Assistance Program - Gilotrif®
The BI Cares Patient Assistance Program - Ofev®
All Other Locations New Hire
Athens New Hire
Jens Barthelmes
My career challenge at Boehringer Ingelheim by Jens Barthelmes. Read it now!
BI & Lilly Announce Outcome of FDA Advisory Meeting | Boehringer Ingelheim US
The EASE phase III program includes two Phase III clinical trials to investigate the efficacy, safety and tolerability of once-daily Empagliflozin.
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH
Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.